Amylyx Pharmaceuticals In... (AMLX)
3.47
0.02 (0.58%)
At close: Jan 29, 2025, 3:59 PM
3.50
0.86%
After-hours Jan 29, 2025, 07:58 PM EST
Cashflow (Annual)
Get detailed ratio statement breakdowns, uncovering price to free cash flow ratio, price per earnings, and much more.
| Year | FY23 | FY22 | FY21 | FY20 | FY19 |
| Net Income | 49.27M | -198.38M | -87.93M | -42.28M | -13.72M |
| Depreciation & Amortization | 1.09M | 487.00K | 52.00K | 1K | n/a |
| Stock-Based Compensation | 37.16M | 21.71M | 3.14M | 243.00K | 108.00K |
| Other Working Capital | -81.54M | 21.58M | 3.92M | 1.18M | 2.22M |
| Other Non-Cash Items | -9.94M | -2.06M | 5.23M | 1.74M | -583.00K |
| Deferred Income Tax | n/a | n/a | 121.00K | 1.00M | n/a |
| Change in Working Capital | -65.66M | -1.64M | 4.59M | 2.60M | 3.50M |
| Operating Cash Flow | 11.92M | -179.87M | -74.80M | -36.70M | -10.69M |
| Capital Expenditures | -1.24M | -2.53M | -353.00K | -151.00K | n/a |
| Acquisitions | n/a | 236.46M | -3.00M | n/a | n/a |
| Purchase of Investments | -300.83M | -415.87M | -49.05M | n/a | n/a |
| Sales Maturities Of Investments | 394.12M | 179.41M | 3.00M | n/a | n/a |
| Other Investing Acitivies | n/a | -236.46M | 3.00M | n/a | n/a |
| Investing Cash Flow | 92.05M | -238.99M | -46.41M | -151.00K | n/a |
| Debt Repayment | n/a | n/a | 25.90M | 16.82M | 641.00K |
| Common Stock Repurchased | -3.31M | n/a | n/a | n/a | n/a |
| Dividend Paid | n/a | n/a | n/a | n/a | n/a |
| Other Financial Acitivies | 3.54M | -658.00K | 132.61M | 30.01M | 27.00K |
| Financial Cash Flow | 3.54M | 431.79M | 158.51M | 46.82M | 668.00K |
| Net Cash Flow | 107.67M | 12.87M | 37.31M | 9.97M | -10.02M |
| Free Cash Flow | 10.68M | -182.40M | -75.15M | -36.85M | -10.69M |